Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma

Radical cystectomy remains the standard curative-intent treatment for most patients with muscle-invasive bladder cancer, but it is associated with significant morbidity and long-term quality-of-life implications. Trimodality therapy is an accepted standard-of-care alternative for carefully selected patients who wish to preserve their bladder; however, optimal patient selection remains challenging.

The combination of enfortumab vedotin plus pembrolizumab (EV-P) has demonstrated remarkable activity in urothelial carcinoma, including in the perioperative setting, with pathologic complete response rates of approximately 50-60%. These results generate the hypothesis that a subset of patients may achieve sufficiently deep responses to allow selective deferral of cystectomy. Cohort A of this trial prospectively evaluates the use of multimodal response assessment (pelvic MRI and TURBT, ctDNA) to guide individualized decisions regarding cystectomy versus bladder preservation.

Radical nephroureterectomy (RNU) remains the standard curative-intent treatment for high-risk upper tract urothelial carcinoma (UTUC), but recurrence rates after surgery alone are high. Neoadjuvant cisplatin-based chemotherapy improves pathologic outcomes and is supported by phase II data, but its delivery is constrained by baseline renal dysfunction and the further decline in glomerular filtration that follows RNU - historically, only about 20% of patients remain cisplatin-eligible postoperatively, which is the principal rationale for delivering platinum in the neoadjuvant rather than adjuvant setting. A large fraction of patients with UTUC are cisplatin-ineligible at baseline, and no level 1 evidence supports a specific neoadjuvant regimen in this population.

EV-P is not constrained by renal function and has produced unprecedented activity in urothelial carcinoma. In the EV-302 upper tract subgroup, EV-P achieved an objective response rate of 67.7% and a complete response rate of 28.6%, with survival benefit preserved relative to platinum-based chemotherapy. In the perioperative bladder cancer setting, EV-P has yielded pathologic complete response rates of approximately 50-60%. However, available data on EV-P in UTUC are restricted to the metastatic setting, and prospective evaluation in the neoadjuvant setting is lacking. Cohort B of this trial addresses this gap by prospectively evaluating neoadjuvant EV-P followed by RNU in patients with high-risk UTUC, with pathologic complete response as the primary endpoint.

Study Overview

• Status: Not yet recruiting
• Conditions: Urothelial Carcinoma (UC)
• Intervention / Treatment: Drug: enfortumab vedotin and pembrolizumab (EV/P)

• Study Type: Interventional
• Enrollment (Estimated): 39
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adults ≥ 18 years of age.
• ECOG Performance Status of 0-2
• For Cohort A, a clinical or pathological diagnosis consistent with muscle-invasive urothelial carcinoma of the bladder (locoregional), with a clinical staging of T2 or higher, N0 to N2, and M0.

For Cohort B, a clinical or pathological diagnosis of upper tract urothelial carcinoma, with high-intermediate risk or higher per NCCN guidelines, planned for definitive surgery.

• High-intermediate: High grade + Unifocal <1.5 cm

• High: High grade + Multifocal or >1.5 cm or high-grade renal obstruction or invasion on axial imaging Any proportion of divergent differentiation is permitted across all histologies (except neuroendocrine - see exclusion criteria), as long as a urothelial component is identified.

  • Eligible to receive enfortumab vedotin plus pembrolizumab (EV-P) in the opinion of the investigators.
  • Written informed consent obtained from the subject and the subject agrees to comply with all the study-related procedures.
  • Subjects must not have more than one active malignancy at the time of enrollment.

Note: Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen or primary endpoint (as determined by the treating physician) are eligible for this trial.

- Subjects of childbearing potential (SOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 4 months after the last dose of EV-P to minimize the risk of pregnancy. Prior to study enrollment, subjects of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.

SOCBP includes any subject who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or who is not post-menopausal. Post-menopause is defined as:

• Amenorrhea that has lasted for ≥ 12 consecutive months without another cause, or

• For subjects with irregular menstrual periods who are taking hormone replacement therapy (HRT), a documented serum follicle-stimulating hormone (FSH) level of greater than 35 mIU/mL.

  • Subjects with partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 4 months following the last dose of EV-P.

Exclusion Criteria:

• Histology that contains any component of neuroendocrine carcinoma.
• Any known contraindications to enfortumab vedotin plus pembrolizumab.
• Subjects who are confirmed to be pregnant or breastfeeding.
• History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.
• Administration of a vaccine containing live virus within 30 days prior to the first dose of trial treatment. Note: Most flu vaccines are killed viruses, with the exception of the intra-nasal vainer (Flu-Mist) which is an attenuated live virus and therefore prohibited for 30 days prior to first dose.
• Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort A (neoadjuvant EV-P + response-adapted management); Following neoadjuvant EV-P, participants in this cohort will have response-adapted management based on if they achieved a composite clinical complete response (cCR) to determine the next step in their treatment on this study. A participant has achieved cCR if ALL the following are met: ctDNA is negative,; Imaging are negative for lymph nodes and distant metastases, and; TURBT shows T0 or Ta low-grade only, and a negative urinary cytology. If a participant achieves cCR, they will have a choice between: receive 5 more cycles of EV-P, followed by pembrolizumab alone to complete 1 year of therapy.; Alternatively, if participant wishes, partial or radical cystectomy. If a participant does not achieve cCR, they will have cystectomy.	Drug: enfortumab vedotin and pembrolizumab (EV/P); Participants in both cohorts will first receive neoadjuvant enfortumab vedotin + pembrolizumab (EV-P) for 4 cycles. Each cycle is 21 days. Participants will be given 1.25 mg/kg enfortumab vedotin intravenously on days 1 and 8 and 200 mg pembrolizumab intravenously on day 1 of each cycle. Participants in Cohort A may then choose to receive 5 more cycles of EV-P followed by pembrolizumab alone to complete 1 year of study therapy if they have a composite complete clinical response. Participants in Cohort B will then receive 5 more cycles of EV-P followed by pembrolizumab alone to complete 1 year of study therapy following their definitive surgery.
Experimental: Cohort B (neoadjuvant EV-P + surgery + adjuvant EV-P)	Drug: enfortumab vedotin and pembrolizumab (EV/P); Participants in both cohorts will first receive neoadjuvant enfortumab vedotin + pembrolizumab (EV-P) for 4 cycles. Each cycle is 21 days. Participants will be given 1.25 mg/kg enfortumab vedotin intravenously on days 1 and 8 and 200 mg pembrolizumab intravenously on day 1 of each cycle. Participants in Cohort A may then choose to receive 5 more cycles of EV-P followed by pembrolizumab alone to complete 1 year of study therapy if they have a composite complete clinical response. Participants in Cohort B will then receive 5 more cycles of EV-P followed by pembrolizumab alone to complete 1 year of study therapy following their definitive surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical complete response rate	Determine the percent of subjects in Cohort A that achieve a clinical complete response following completion of neoadjuvant EV-P. A clinical complete response is defined as having all three of the following: A negative ctDNA result,; Imaging of the pelvis with negative lymph nodes and no distant metastasis on CT scans, AND; A TURBT showing T0 or low-grade Ta only, and a negative urinary cytology.	3 weeks following completion of neoadjuvant therapy
Pathologic complete response rate	Determine the percent of subjects in Cohort B who achieve a pathologic complete response at the time of surgery. A pathologic complete response is defined as having disease staging of pT0N0 at time of surgery.	8 weeks following completion of neoadjuvant therapy

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Event-free survival	Determine the event-free survival of patients in Cohort A at 1 year from the start of EV-P	1 year from the start of EV-P
Event-free survival	Determine the event-free survival of patients in Cohort A at 2 years from the start of EV-P	2 years from the start of EV-P
Overall survival	Determine the overall survival of patients in Cohort A at 1 year from the start of EV-P	1 year from the start of EV-P
Overall survival	Determine the overall survival of patients in Cohort A at 2 years from the start of EV-P	2 years from the start of EV-P
Bladder-intact survival	Determine the bladder-intact survival of patients in Cohort A at 1 year from the start of EV-P	1 year from the start of EV-P
Bladder-intact survival	Determine the bladder intact survival of patients in Cohort A at 2 years from the start of EV-P	2 years from the start of EV-P
Pathological complete response	Determine number of subjects in cohort A who achieve a pathological complete response after first 4 cycles of EV-P.	After completion of first 4 cycles of EV-P (each cycle of EV-P is 21 days)
Pathologic downstaging	Determine number of patients in cohort A who achieve pathological downstaging (disease staging <pT2N0) after the first 4 cycles of EV-P	At completion of first 4 cycles of EV-P (each cycle of EV-P is 21 days)
Event-free survival	Determine the event-free survival of patients in Cohort B at 2 years from the start of EV-P	2 years from the start of EV-P
Overall survival	Determine the overall survival of patients in Cohort B at 2 years from the start of EV-P	2 years from the start of EV-P
Pathologic downstaging	Determine number of patients in cohort B who achieve pathological downstaging (disease staging <pT2N0) after the first 4 cycles of EV-P	At completion of first 4 cycles of EV-P (each cycle of EV-P is 21 days)

Collaborators and Investigators

• Sponsor: University of Florida
• Investigators: Principal Investigator: Daniel Araujo, MD, University of Florida

Study record dates

Study Major Dates

• Study Start (Estimated): October 1, 2026
• Primary Completion (Estimated): February 1, 2029
• Study Completion (Estimated): October 1, 2030

Study Registration Dates

• First Submitted: June 3, 2026
• First Submitted That Met QC Criteria: June 8, 2026
• First Posted (Actual): June 11, 2026

Study Record Updates

• Last Update Posted (Actual): June 11, 2026
• Last Update Submitted That Met QC Criteria: June 8, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: bladder cancer; pembrolizumab; urothelial carcinoma; upper tract urothelial carcinoma; cystectomy; enfortumab vedotin; muscle invasive bladder cancer
• Additional Relevant MeSH Terms: Urogenital Diseases; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Male Urogenital Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Urologic Neoplasms; Carcinoma; Urinary Bladder Diseases; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; pembrolizumab; enfortumab vedotin
• Other Study ID Numbers: UF-GU-014

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No